NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGIO shares have decreased by 13.4% and is now trading at $35.40. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its quarterly earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to analysts' expectations of $33.72 million. Agios Pharmaceuticals had a negative return on equity of 73.42% and a negative net margin of 348.96%. The company's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.58) earnings per share. View Agios Pharmaceuticals' earnings history.

12 Wall Street analysts have issued 12-month price objectives for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $79.00. On average, they expect Agios Pharmaceuticals' stock price to reach $63.10 in the next year. This suggests a possible upside of 78.2% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

Media headlines about AGIO stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAgios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Mylan (MYL), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), bluebird bio (BLUE), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), Micron Technology (MU) and AbbVie (ABBV).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.99%), Capital International Investors (7.70%), State Street Corp (3.20%), First Trust Advisors LP (2.60%), Farallon Capital Management LLC (2.12%) and ArrowMark Colorado Holdings LLC (1.88%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Capital International Inc. CA, Capital Bank & Trust Co, Alliancebernstein L.P., Casdin Capital LLC, Handelsbanken Fonder AB, Capital International Investors, and Rhenman & Partners Asset Management AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, and Scott Biller. View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Norges Bank, Perceptive Advisors LLC, First Trust Advisors LP, Macquarie Group Ltd., Macquarie Group Ltd., Bank of America Corp DE, and Nuveen Asset Management LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse. View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $35.40.

Agios Pharmaceuticals has a market capitalization of $2.43 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe. View additional information about Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]